Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DURECT Corporation DRRX
$4.77
-$0.17 (-3.64%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
122057227.00000000
-
week52high
9.70
-
week52low
3.17
-
Revenue
19283000
-
P/E TTM
-3
-
Beta
1.59653900
-
EPS
-1.53000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 05 мая 2021 г. | |
| Chardan Capital | Buy | Buy | 03 февр 2021 г. |
| Chardan Capital | Buy | 30 окт 2020 г. | |
| Roth Capital | Buy | 12 окт 2020 г. | |
| Oppenheimer | Outperform | 31 июл 2020 г. | |
| Oppenheimer | Outperform | Outperform | 07 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Robertson Judith J. | A | 356132 | 9412 | 19 авг 2022 г. |
| Robertson Judith J. | A | 346720 | 71531 | 18 авг 2022 г. |
| Robertson Judith J. | A | 275189 | 8130 | 17 авг 2022 г. |
| Robertson Judith J. | A | 267059 | 2059 | 17 авг 2022 г. |
| Maderis Gail J | A | 200000 | 25204 | 12 авг 2022 г. |
| Maderis Gail J | A | 174796 | 24796 | 11 авг 2022 г. |
| Maderis Gail J | A | 150000 | 79693 | 10 авг 2022 г. |
| Maderis Gail J | A | 70307 | 70307 | 09 авг 2022 г. |
| Papp Timothy M. | A | 600000 | 600000 | 01 июл 2022 г. |
| AZAB MOHAMMAD | A | 55000 | 55000 | 15 июн 2022 г. |
Новостная лента
DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript
Seeking Alpha
08 мая 2023 г. в 22:42
DURECT Corporation (NASDAQ:DRRX ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Tim Papp - Chief Financial Officer Jim Brown - Chief Executive Officer Keith Lui - Senior Vice President, Business Development, Commercial, Medical Affairs WeiQi Lin - Executive Vice President, Research and Development, Principal Scientist Norman Sussman - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Ed Arce - H.C. Wainwright Francois Brisebois - Oppenheimer Sean Kim - Jones Trading Operator Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call.
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:02
Durect (DRRX) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.50 per share a year ago.
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
PRNewsWire
01 мая 2023 г. в 19:03
CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023.
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
PRNewsWire
25 апр 2023 г. в 18:45
CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C.
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
07 мар 2023 г. в 18:48
Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?